A Phase 3, Randomized, Placebo‐Controlled Evaluation of the Safety of Intravenous Meloxicam Following Major Surgery

Overview of attention for article published in Clinical Pharmacology in Drug Development, February 2019

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#14 of 464)
High Attention Score compared to outputs of the same age (94th percentile)
High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

news: 6 news outlets

twitter: 1 X user

Readers on

mendeley: 83 Mendeley

So far, Altmetric has seen 8 news stories from 6 outlets.

Recro Pharma Announces Publication of Phase III IV Meloxicam Clinical Safety and Opioid Use Data in the Journal Clinical Pharmacology in Drug Development

Morning Star, 25 Feb 2019

MALVERN, Pa., Feb. 25, 2019 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical…

Recro Pharma Announces Publication of Phase III IV Meloxicam Clinical Safety and Opioid Use Data in the Journal Clinical Pharmacology in Drug Development

TMCnet.com, 25 Feb 2019

MALVERN, Pa., Feb. 25, 2019 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical…

Recro Pharma Announces Publication of Phase III IV Meloxicam Clinical Safety and Opioid Use Data in the Journal Clinical Pharmacology in Drug Development

Benzinga, 25 Feb 2019

MALVERN, Pa., Feb. 25, 2019 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical…

Recro Pharma Announces New IV Meloxicam Data Publication in the Journal Regional Anesthesia

BioTech Gate, 20 Feb 2019

Publication Highlights a Pooled Analysis of IV Meloxicam’s Safety and Opioid-Reducing Effects Across Three Phase III and Four…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 4 additional news stories.